Labcorp Accelerates Adoption of Decentralized Trials Through Alliance with Medable


Applied Clinical Trials

LabCorp, a global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, is expanding its technology ecosystem to accelerate the adoption of decentralized clinical trials, often referred to as hybrid and virtual clinical trials.

Covance is expanding its decentralized trials technology ecosystem through an alliance with Medable, a software provider for digital clinical trials. The Covance patient and site interface will be powered by Medable’s modular software platform, providing immediate access to applications that will allow patients to participate in decentralized clinical trials. The platform will also enable data and system interoperability, facilitate remote data collection and engagement between patients, sites, and clinical investigators.

“Working together, we can apply the full capabilities of LabCorp Diagnostics business, Covance, and our technology ecosystem to extend patient access, improve the patient experience, and accelerate timelines for clinical development,” said Bill Hanlon, Ph.D., president, Enterprise Solutions, Covance.  “We will continue to play a critical role as aggregators and integrators to provide customers with the access, flexibility, and scale necessary to enable global decentralized studies, and to rapidly innovate in ways that improve the patient experience and trial efficiency.”

According to Medable, the clinical trials landscape is rapidly changing and trials need to be more accessible and more convenient for participants. Through this partnership, the companies are creating a data-driven, decentralized trial ecosystem.

“Working with LabCorp Diagnostics and Covance allows us to deepen patient engagement and reduce burden for trial participants, and this decentralized trial ecosystem will help us get effective therapies to patients faster,” said Michelle Longmire, MD, and co-founder and CEO, Medable. “This innovative ecosystem will accelerate trial timelines.” 

In late 2019, Covance unveiled its latest solution to help transform the conduct of decentralized clinical trials. The company’s cohesive decentralized clinical trials solution integrates unique capabilities from across Covance and LabCorp Diagnostics, redefining the patient experience to increase participation. It provides a patient-centric ecosystem of conveniently located resources, such as LabCorp’s U.S.-based Patient Service Centers and LabCorp at Walgreens locations, global partnerships with reputable retail pharmacies, as well as home health phlebotomy and nursing service providers, all connected by a best-in-class technology platform. 

“Covance is committed to innovation and has extensive experience conducting decentralized trials,” continued Dr. Hanlon. “We will continue to expand our technology ecosystem through development and incorporation of best-in-class technology solutions to support connected devices and digital biomarkers to fully realize the promise of decentralized clinical trials.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.